- The acquisition will deliver strong commercial synergy with Hasten’s current critical care portfolio

Shanghai, May 4th , 2023 – Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.

Under the agreement, Hasten acquired Roche’s China mainland rights for Rocephin®, including the product’s Marketing Authorization, Intellectual Property, trademarks, and technology transfer. As a critical care product, Rocephin® is a broad-spectrum antibiotic with strong brand value for community acquired infections.

“Hasten is committed to building a leading innovative medical and healthcare enterprise in China. The acquisition of Rocephin® delivers strong commercial synergy with Hasten’s current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients,” Summer Xia, CEO of Hasten Biopharma, said.

Hasten is an investment of CBC Group, Asia's largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.